To continue reading this content, please enable JavaScript in your browser settings and refresh this page. In April 2021, the FDA approved the 100th monoclonal ...

In the last few years, multispecific antibodies, such as bispecific, trispecific, and tetraspecific antibodies, have become the breakthrough stars in antibody therapeutics. Compared with conventional ...

In the not-too-distant past, scientists in biological research found themselves burdened with the time-consuming tasks of developing, purifying, and characterizing the antibodies they worked with in ...

Alloy Therapeutics, Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting-edge drug ...

In the ongoing Omicron era, a new Covid-19 antibody could renew optimism for urgently required SARS-CoV-2 monoclonal therapies. Over the last three years, various ...

VICTORIA, British Columbia--(BUSINESS WIRE)-- ImmunoPrecise Antibodies Ltd. (the “Company” or “IPA”) (NASDAQ: IPA), a leader in AI-driven medical innovation, is proud to announce a significant ...

With the mAb therapeutic market expected to reach $300 billion by 2025, their role in transforming the therapeutic landscape ...

Adagene Inc. has announced a partnership with ConjugateBio Inc. to provide a proprietary antibody for the development of innovative bispecific antibody-drug conjugates (ADCs). Adagene's CEO ...

A lack of targeting specificity has been a long-running problem for cytotoxic anticancer agents, with excess side effects limiting their effectiveness. Scientists have turned to antibodies, and their ...

Insourcing cell-line development has helped a fast-growing antibody manufacturer to deliver process improvements and strengthen communication with their contract manufacturer, according to Genmab, ...